These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 16075823)

  • 21. Dyslipidaemia: cardiovascular prevention--end of the road for niacin?
    Tuteja S; Rader DJ
    Nat Rev Endocrinol; 2014 Nov; 10(11):646-7. PubMed ID: 25178730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating mixed dyslipidemias: why and how.
    Ballantyne CM
    Clin Cardiol; 2001; 24(7 Suppl):II-6-9. PubMed ID: 11444652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model.
    Ryan MJ; Gibson J; Simmons P; Stanek E
    Am J Cardiol; 2003 Jun; 91(12):1427-31. PubMed ID: 12804728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
    Robinson JG
    Vasc Health Risk Manag; 2009; 5(1):31-43. PubMed ID: 19436666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
    Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
    Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2.
    Taylor AJ; Zhu D; Sullenberger LE; Lee HJ; Lee JK; Grace KA
    Vasc Health Risk Manag; 2007; 3(1):159-64. PubMed ID: 17583186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
    McKenney JM
    Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-density lipoprotein particles, coronary heart disease, and niacin.
    Asztalos BF
    J Clin Lipidol; 2010; 4(5):405-10. PubMed ID: 21122684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of hypercholesterolaemia in postmenopausal women.
    Davidson MH; Maki KC; Karp SK; Ingram KA
    Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Shah S; Ceska R; Gil-Extremera B; Paolini JF; Giezek H; Vandormael K; Mao A; McCrary Sisk C; Maccubbin D
    Int J Clin Pract; 2010 May; 64(6):727-38. PubMed ID: 20518948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease.
    Davidson MH
    Am Heart Hosp J; 2007; 5(4):210-6. PubMed ID: 17982304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of low HDL-cholesterol levels in the reduction of cardiovascular risk].
    Stokić E; Marinkov J
    Med Pregl; 2007; 60(3-4):145-50. PubMed ID: 17853726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy in dyslipidemia: where are we now?
    Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
    Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.
    Jacobson TA
    Mayo Clin Proc; 2011 Aug; 86(8):762-80. PubMed ID: 21803958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.